PRME Prime Medicine, Inc.


$ 3.66 $ -0.06 (-1.63 %)    

Friday, 21-Nov-2025 15:56:21 EST
QQQ $ 589.60 $ 4.40 (0.75 %)
DIA $ 462.45 $ 5.05 (1.1 %)
SPY $ 658.47 $ 6.50 (1 %)
TLT $ 89.50 $ 0.27 (0.3 %)
GLD $ 373.70 $ -0.58 (-0.15 %)
$ na
$ 3.60
$ 3.67 x 600
$ 3.68 x 1,133
$ 3.43 - $ 3.72
$ 1.11 - $ 6.94
2,745,314
na
nm
$ 2.20
nm
TBD
na
na (nm)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 citigroup-maintains-neutral-on-prime-medicine-lowers-price-target-to-425

Citigroup analyst Samantha Semenkow maintains Prime Medicine (NASDAQ:PRME) with a Neutral and lowers the price target from $...

 chardan-capital-maintains-buy-on-prime-medicine-lowers-price-target-to-9

Chardan Capital analyst Geulah Livshits maintains Prime Medicine (NASDAQ:PRME) with a Buy and lowers the price target from $...

 my-top-biotech-stock-picks-and-portfolio-strategy-for-the-next-3-10-years

Forecasts in biotech market indicate that by 2030, gene therapy will become more accessible, potentially generating hundreds of...

 chardan-capital-maintains-buy-on-prime-medicine-lowers-price-target-to-10

Chardan Capital analyst Geulah Livshits maintains Prime Medicine (NASDAQ:PRME) with a Buy and lowers the price target from $...

 prime-medicine-q2-eps-041-misses-039-estimate-sales-1115m-beat-750000k-estimate

Prime Medicine (NASDAQ:PRME) reported quarterly losses of $(0.41) per share which missed the analyst consensus estimate of $(0....

 prime-medicine-announces-proposed-public-offering-of-common-stock-no-size-or-amount-disclosed

Prime Medicine, Inc. (NASDAQ:PRME), a biotechnology company committed to delivering a new class of differentiated one-time cura...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION